Peptides Take Center Stage in a US Biotech Revival

Sethera and CordenPharma lead a peptide resurgence reshaping US drug manufacturing

5 Nov 2025

The US peptide drug industry is entering a new phase of expansion, driven by technological innovation and major investment in large-scale production. Once viewed as too costly and complex, peptides are now becoming central to drug development for conditions such as diabetes, obesity and cancer.

Sethera Therapeutics, a biotechnology company based in the US, is emerging as one of the sector’s most active players. Its partnership with the University of Utah has produced an enzyme-based platform designed to simplify peptide synthesis and shorten development timelines. The technology, currently in preclinical testing, could help make peptide manufacturing more efficient and scalable.

In a parallel move, CordenPharma announced in July 2024 that it had secured roughly €3bn in long-term peptide manufacturing contracts. The company, a leading contract development and manufacturing group, said the deals reflect growing demand from pharmaceutical clients seeking reliable peptide supply at industrial scale.

“Companies aren’t just making single peptides anymore,” said Lisa Carr, market analyst at BioInvest Research. “They’re building platforms that churn out entire pipelines faster and cleaner than ever before. It’s the biologics boom all over again, only sharper and quicker.”

Advances in continuous and enzyme-driven synthesis are transforming peptides from unstable, niche products into commercially viable therapies. The shift promises more consistent production, reduced costs and broader patient access. For investors, analysts say, the appeal lies in more predictable pipelines and a lower risk profile.

Still, rapid innovation presents challenges. Integrating new technologies and managing intellectual property will require close collaboration across the biotech and pharmaceutical sectors. “This isn’t a passing trend,” said David Lin, a pharmaceutical strategy consultant. “It’s a structural shift in how drugs are made, and the US is setting the pace.”

Analysts expect strong growth in peptide therapeutics through 2030, supported by sustained investment and accelerating demand. As research partnerships deepen and manufacturing methods mature, peptides are moving from scientific curiosity to a key pillar of modern medicine.